Search results
Results From The WOW.Com Content Network
Total equity. US$699.14 million (2019) Number of employees. 570 (June 30, 2020) Website. acadia .com. Footnotes / references. [1] Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.
Pimavanserin. Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being studied for the treatment of Alzheimer's disease psychosis, schizophrenia, agitation, and major depressive disorder. [3] Unlike other antipsychotics, pimavanserin is ...
Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the ...
AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a K i of 5 nM, and no significant affinity for any other receptors tested.
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NAS: ACAD) , a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related ...
Acadia has an antipsychotic drug sold under the brand name Nuplazid approved for patients with a type of Parkinson's disease. The company's shares clawed back some lost ground and were last down 2.1%.
Acadia Pharmaceuticals; Accelrys / Biovia (acquired by Dassault Systems) Allerca; Amylin Pharmaceuticals; Apricus Biosciences; Arena Pharmaceuticals; Cytori Therapeutics; Genesee Scientific; Genomics Institute of the Novartis Research Foundation; Halozyme Therapeutics; Hologic; Illumina; Integrated Genetics; InvivoGen; La Jolla Institute for ...
What: Shares of ACADIA Pharmaceuticals -- a. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. Mail. Sign in. Subscriptions ...